Affiliation:
1. Central International Intellectual Property Co., Ltd., Baotou 014030, China
Abstract
Background:
KRAS and BRAF targets are involved in the epidermal growth factor
receptor pathway. KRAS and BRAF targets are the most frequent driver mutations in cancer.
Objective:
The objective of the study was to present the recent developments in the KRAS target
and the BRAF target.
Method:
KRAS target and BRAF target were analyzed by US patent analysis. All US granted
patent documents from January 2002 to November 2021 were retrieved.
Results:
The results showed both KRAS and BRAF targets to be attractive targets for developing
anticancer drugs. The technology of RNA interference has been developed for drug discovery related
to the KRAS target. Our study indicates that the structural screening of inhibitors between
the KRAS target and the BRAF target should be an inverse option.
Conclusion:
The chemical structures of inhibitors of BRAF target exhibited a unique classification
of C07D405. The inhibitors of BRAF target could be used for the treatment of various cancers.
However, the inhibitors of KRAS target did not show this feature. The present study provides
new insight into drug discovery involving KRAS and BRAF targets.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献